Summary & Overview
HCPCS Q2049: Doxorubicin Hydrochloride Liposomal (Lipodox), 10 mg Injection
HCPCS Level II code Q2049 denotes an injection of doxorubicin hydrochloride, liposomal (imported Lipodox), in 10 mg units. As a specialized chemotherapeutic agent, this code is used when billing for the drug itself when administered in outpatient infusion settings. Nationally, precise drug coding for liposomal doxorubicin supports accurate reimbursement, utilization tracking, and clinical reporting for oncology care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, benchmarks for payer coverage and reimbursement approaches where available, and relevant billing considerations tied to drug unitization and site-of-service use. The publication outlines typical coding practice for a 10 mg packaged unit of imported Lipodox and highlights areas where payer policy or clinical documentation can affect claim adjudication.
This resource is intended for billing managers, practice administrators, and revenue cycle professionals seeking a national-level reference for handling HCPCS Level II code Q2049 for liposomal doxorubicin injections in outpatient oncology infusion settings.
Billing Code Overview
HCPCS Level II code Q2049 represents an injection of doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg. This service is a chemotherapeutic drug administration for a liposomal formulation of doxorubicin supplied in 10 mg increments.
Service type: Drug administration — chemotherapy (intravenous infusion or injection)
Typical site of service: Hospital outpatient infusion center or physician office infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor or recurrent epithelial ovarian cancer, metastatic breast cancer, or Kaposi sarcoma receiving intravenous chemotherapy with liposomal doxorubicin (Q2049, 10 mg vial of imported Lipodox). The patient arrives to an outpatient infusion center or hospital outpatient oncology infusion suite for preparation and administration. Pre-infusion workflow includes verification of diagnosis and prior authorization, assessment of performance status, review of current labs (complete blood count, hepatic function tests), and confirmation of vascular access (peripheral IV or central line). Pharmacy compounds the dose per weight or body surface area using aseptic technique and dispenses syringes/vials and infusion tubing. The infusion nurse performs time-out, documents pre-medications if indicated (antiemetic, corticosteroid, H2 blocker), and initiates infusion with monitoring for infusion reactions, extravasation risk, myelosuppression, mucositis, and cardiotoxicity. Post-infusion care includes observation for delayed infusion reactions, disposition instructions, scheduling of follow-up labs and oncology clinic visit, and documentation of administered Q2049 dose, lot number, and route in the medical record and claim form.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard use |